Bundling next-generation cancer therapies for synergy

Article Abstract:

Biotech companies are striving to go beyond the limitations of existing targeted therapies either by finding complementary treatments or by combining already approved therapies to synergize their effect. They are seeking optimal biological dose and drug combinations, which give the clinician a lot of control over side effects, as individual dosages can be adjusted.

Drugs, HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Innovations, Biotechnology industry, Biotechnology industries, Cancer, Cancer treatment

---

Nanotech under scrutiny, but tighter regulation remains distant

Article Abstract:

The U.S. Environmental Protection Agency (EPA) and the U.S. Food and Drug Administration (FDA) feel the need for extensive research to determine the human and environmental hazards of nanotech/nanobiotech industry. The health and environmental implications of nano-materials should be researched upon for their safe use in medical and pharmaceutical industry.

Legal issues & crime, Government regulation (cont), Government regulation, Legal/Government Regulation, Commercial physical research, Company legal issue, Laws, regulations and rules, Investigations, Environmental aspects, United States. Environmental Protection Agency, United States. Food and Drug Administration, Nanotechnology industry

---

Ultrafast DNA sequencing

Article Abstract:

A high quality human genome sequence currently costs between $25 and $50 million. To detect single nucleotide polymorphisms (SNPs), increasing emphasis is focused on technologies for genotyping or reseauencing specific areas of the genome.

Product quality, Commodity & service prices, Methods, Prices and rates, Quality management, Technology application, Genotype, Genotypes, Nucleotide sequence, Base sequence, Company pricing policy, Nucleotide sequencing

Similar abstracts:

• Abstracts: Competing for securities underwriting mandates: banking relationships and analyst recommendations. Evidence of information spillovers in the production of investment banking services
• Abstracts: Defense industry seen losing design capability. Co. is sixth-largest contractor: BAE aims for U.S. growth; shuns sales to China, action on Airbus
• Abstracts: Trading on traditional medicines: developing countries could exploit traditional medicine to kick-start biotech, but only if their products measure up to the demands of Western regulators
• Abstracts: The number on biotech indexes. Putting biotech risk in its place. Going short on biotech
• Abstracts: Reagent safety issues surface for cell/tissue therapies. Network aims to knit disparate European initiatives. Biotech awaits single European financial market

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.